Market revenue in 2020 | USD 365.7 million |
Market revenue in 2028 | USD 711.4 million |
Growth rate | 8.7% (CAGR from 2020 to 2028) |
Largest segment | Immunological disorders |
Fastest growing segment | Endocrine & Metabolism Diseases |
Historical data covered | 2016 - 2019 |
Base year for estimation | 2020 |
Forecast period covered | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Immunological disorders was the largest segment with a revenue share of 12.69% in 2020. Horizon Databook has segmented the North America rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
Factors such as high incidence of rare diseases, large number of rare disease registries, presence of substantial numbers of R&D facilities for rare & ultra rare diseases, and extensive investments in diagnosis of rare diseases in countries of North America have driven the revenue in this region.
In addition, increase in collaborations between companies to extend their testing services across the region is driving the revenue share. For instance, in September 2019,. ARCHIMED life Medical Laboratory entered in a mutually beneficial partnership with Blueprint Genetics to combine biochemical testing with genetic testing to drive clinical research.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America rare disease genetic testing market , including forecasts for subscribers. This continent databook contains high-level insights into North America rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account